Mirum shares slipped after announcing an up-to-$820 million deal to acquire Bluejay Therapeutics and its late-stage HDV drug Brelovitug. Wall Street viewed the acquisition favourably, calling it a strong move into rare disease. Mirum also raised $200 million to support development and commercial plans, with the transaction expected to close in early 2026.